Valuation: Personalis, Inc.

Market Cap 1.69B 1.51B 1.4B 1.27B 2.37B 161B 2.41B 16.85B 6.67B 84.24B 6.35B 6.22B 267B P/E 2026 *
-14.6x
P/E 2027 * -16.4x
Enterprise Value 1.52B 1.35B 1.25B 1.13B 2.12B 144B 2.16B 15.08B 5.97B 75.4B 5.69B 5.57B 239B EV / Sales 2026 *
18x
EV / Sales 2027 * 14.5x
Free-Float
74.24%
Yield 2026 *
-
Yield 2027 * -
1 day+0.19%
Current month-2.46%
1 month-2.70%
3 months+32.55%
6 months+166.44%
Current year+99.50%
1 week 15.62
Extreme 15.625
16.12
1 month 15.5
Extreme 15.505
16.59
Current year 4.96
Extreme 4.955
18.89
1 year 4.96
Extreme 4.955
18.89
3 years 0.89
Extreme 0.8906
18.89
5 years 0.89
Extreme 0.8906
21.69
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 58 02/03/2023
Chief Executive Officer 66 31/12/2022
President 56 13/03/2026
Director TitleAgeSince
Director/Board Member 80 01/05/2019
Chairman 76 17/05/2022
Director/Board Member 72 06/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
18/9/26 Sell

Chief Financial Officer

-2,931 0.0028%
18/9/26 Sell

Chairperson

-3,998 0.0038%
18/9/26 Sell

Chief Executive Officer

-7,459 0.0071%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%0.00%+64.05%+1,472.28% 1.69B
-1.01%-0.16%+12.23%+36.11% 120B
-0.80%+2.28%-0.56%+109.76% 102B
+0.24%+1.37%+110.64%+936.88% 58.23B
+0.47%+2.27%-5.92%+84.55% 29.08B
+0.29%+3.47%+19.68%+60.21% 26.68B
+0.44%+3.42%+34.78%+85.09% 26.61B
+0.19%+0.96%+24.42%+403.56% 21.62B
+5.16%+0.90%-18.01%-3.45% 19.86B
-19.92%-19.22%-17.70%+52.99% 18.93B
Average -1.46%+1.55%+22.36%+323.80% 42.38B
Weighted average by Cap. -0.99%+1.78%+21.40%+208.82%

Financials

2026 *2027 *
Net sales 84.34M 75.42M 69.78M 63.18M 118M 8.02B 120M 840M 332M 4.2B 317M 310M 13.29B 110M 98.47M 91.1M 82.48M 154M 10.48B 157M 1.1B 434M 5.48B 413M 404M 17.35B
Net income -114M -102M -94.37M -85.45M -160M -10.85B -163M -1.14B -449M -5.68B -428M -419M -17.97B -103M -92.16M -85.26M -77.2M -144M -9.81B -147M -1.03B -406M -5.13B -387M -379M -16.24B
Net Debt -178M -159M -147M -133M -249M -16.9B -253M -1.77B -699M -8.84B -667M -652M -27.98B -91.04M -81.41M -75.32M -68.19M -128M -8.66B -130M -906M -359M -4.53B -342M -334M -14.34B
Projected Income Statement - Annual - Personalis, Inc.
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
27/10/26 USD 15.88 +0.19% 1,140,587
23/10/26 USD 15.85 +0.19% 1,115,864
22/10/26 USD 15.82 -0.50% 2,694,769
21/10/26 USD 15.90 -0.25% 2,792,190
20/10/26 USD 15.94 +0.38% 2,380,280
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Personalis, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
15.85USD
Average target price
15.17USD
Spread / Average Target
-4.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Personalis, Inc.
  1. Stock Market
  2. Stocks
  3. PSNL Stock